Details for Patent: 9,872,854

Which drugs does patent 9,872,854 protect, and when does it expire?

Patent 9,872,854 protects OTEZLA and is included in one NDA.

Protection for OTEZLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in eight countries.

Summary for Patent: 9,872,854

Title:	Methods for the treatment of psoriatic arthritis using apremilast
Abstract:	Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent.
Inventor(s):	Day; Robert (Newtown, PA)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/209,874
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,872,854
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 9,872,854

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	AB	RX	Yes	No					Y
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	AB	RX	Yes	No					Y
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	AB	RX	Yes	Yes					Y

International Family Members for US Patent 9,872,854

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014235273
Brazil	112015020584
China	105050624